Effect of canonical aryl hydrocarbon receptor pathway inhibitor on human umbilical vein endothelial cells
To study the effect of blockade of canonical aryl hydrocarbon receptor (AHR) pathway in human endothelial cells, we treated human umbilical vein endothelial cells (HUVECs) with a canonical AHR inhibitor, Stemreginin 1 (SR1) and performed bulk RNAseq analysis. Overall design: Samples were derived from 3 individual patients. Cells from each patient were treated with either 1: 10, 000 DMSO (vehicle), or 0.5uM SR1 in 1: 10, 000 DMSO. After 48 hours, RNA samples were collected for comparisons.